Chad Messer

Work

Analyst Chad Messer works at NEEDHAM and is focused on the Healthcare sector with 243 price targets and ratings documented since 2012 spanning on 17 stocks. Analyst's average stock valuation to be materialised ratio is 51.62% with an average time for price targets to be met of 168.56 days.

Most recent stock forecast was given on CRMD, CorMedix, Inc at 11-Nov-2022.

Chad Messer best performing recommendations are on GNCA (GENOCEA BIOSCIENCES, INC).
The best stock recommendation documented was for GNCA (GENOCEA BIOSCIENCES, INC) at 3/5/2014. The price target of $176 was fulfilled within 2 days with a profit of $45.04 (34.39%) receiving and performance score of 171.96.

Average potential price target upside

AGIO AKBA ARQL CYTK ESPR EXEL GNCA IONS PGNX PHAS SGEN SRPT VCEL CRMD GTHX MREO AGLE
AGIO AKBA ARQL CYTK ESPR EXEL GNCA IONS PGNX PHAS SGEN SRPT VCEL CRMD GTHX MREO AGLE